BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//c-myc - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://cmyc.w.uib.no
X-WR-CALDESC:Events for c-myc
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Oslo
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Oslo:20251113T143000
DTEND;TZID=Europe/Oslo:20251113T153000
DTSTAMP:20260530T201224
CREATED:20251113T093610Z
LAST-MODIFIED:20251113T094238Z
UID:984-1763044200-1763047800@cmyc.w.uib.no
SUMMARY:CCBIO and CMYC seminar
DESCRIPTION:“Stress for success”: Unlocking Venetoclax sensitivity in T-ALL through the mTORC1–ISR–BMF axis.\n\n\n\nby Prof. Vincenzo Ciminale\, MD\, Istituto Oncologico Veneto\, Padova\, Italy\n\n\n\n\n\nWhen: Thursday\, 13.11.2025\, 14.30–15.30 \n\n\n\nWhere: Aud. 4\, BBB \n\n\n\nHost: Bjørn Tore Gjertsen \n\n\n\nAbstract\n\n\n\nRefractory/relapsed T-cell acute lymphoblastic leukemia (R/R T-ALL) remains a major therapeutic challenge at present. Our recent studies showed that inhibition of mTORC1 markedly sensitizes T-ALL cell lines and patient-derived xenografts (PDXs) to the BCL-2 inhibitor Venetoclax. RNAseq\, gene set enrichment analysis\, and analysis of the temporal trajectories of response to the mTORC1 inhibitor Everolimus revealed that induction of cell death was dependent on sustained engagement of the integrated stress response (ISR)\, resulting in induction of BMF\, a proapoptotic protein of the BCL-2 family. The effects on cell death were phenocopied by the bisteric mTORC1 inhibitor RMC6272 or by genetic silencing of the mTORC1 cofactor Raptor. Genetic silencing of the ISR master regulator ATF4 also phenocopied these effects\, confirming ISR engagement as a critical mediator of cytotoxicity. Conversely\, epigenetic silencing or siRNA-mediated knockdown of BMF conferred resistance to Everolimus\, whereas histone deacetylase inhibition restored BMF expression and drug sensitivity. Combined treatment with Everolimus and Venetoclax elicited potent\, ISR-dependent antitumor activity in vivo. \n\n\n\nThese findings provide insight into the links between mTORC1 and the ISR and furnish proof-of-concept evidence for mTORC1 inhibition and sustained ISR activation as a viable strategy to overcome Venetoclax resistance to in T-ALL. Expression of BMF\, a key mediator of this process\, could predict response to this combination therapy. \n\n\n\nRead more on CCBIO’s website.
URL:https://cmyc.w.uib.no/event/ccbio-and-cmyc-seminar/
CATEGORIES:Networking Activities,Seminar
END:VEVENT
END:VCALENDAR